Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTHFD2 | P13995 | 9/20 | 0.73 |
| ▸ | DRD4 | P21917 | 6/20 | 0.56 |
| ▸ | DRD2 | P14416 | 4/20 | 0.48 |
| ▸ | DRD3 | P35462 | 4/20 | 0.48 |
| ▸ | MTHFD1 | P11586 | 4/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24439479 | 0.85 | MTHFD2 (1.00) | MTHFD2DRD4MTHFD1 | |
| SCHEMBL30825595 | 0.85 | MTHFD2 (1.00) | MTHFD2DRD4MTHFD1 | |
| SCHEMBL5507692 | 0.83 | MTHFD2 (0.52) | MTHFD2DRD4MAPTNPC1KDM4E | |
| SCHEMBL10811259 | 0.79 | MTHFD2 (0.55) | MTHFD2DRD4DRD2DRD3ERN1 | |
| SCHEMBL21354091 | 0.73 | KDM4E (0.62) | MTHFD2MTHFD1ERN1KDM4EALDH1A1 | |
| SCHEMBL5378293 | 0.72 | MTHFD2 (0.73) | MTHFD2MAPTKDM4EALDH1A1GAA | |
| SCHEMBL11762718 | 0.72 | MAOA (0.60) | MTHFD2MAPTKDM4EALDH1A1GAA | |
| SCHEMBL7562741 | 0.72 | KDM4E (0.60) | MAPTKDM4EALDH1A1GAAHPGD | |
| SCHEMBL10811537 | 0.71 | DRD4 (0.50) | MTHFD2DRD4DRD2DRD3 | |
| SCHEMBL28360801 | 0.71 | CYP1A2 (0.61) | KDM4EALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | claimed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | claimed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | claimed |
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | MTHFD2 2084/4885DRD4 4276/4885DRD2 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.